Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') today announced that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, ...
Authorities say group planned sabotage operations, recruited Emirati youth and channelled funds to suspicious foreign ...
Cavendish Maxwell's report said hotels in Oman welcomed 2.4 million guests last year, up nearly 11 per cent from 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results